A 2026 laboratory study found that a genetic molecule called circBRWD1 drives plaque buildup in arteries by triggering excessive inflammation in immune cells. When researchers blocked circBRWD1 in mice with heart disease, plaque size decreased and inflammation markers dropped significantly. According to Gram Research analysis, this discovery identifies a new potential target for future heart disease treatments, though human studies are still needed before any new drugs can be developed.
Scientists have discovered that a special type of genetic material called circBRWD1 plays a major role in making heart disease worse. Using mice and lab studies, researchers found that this genetic trigger causes immune cells in the body to become overly inflamed, which speeds up the buildup of dangerous plaque in arteries. When they turned off this genetic trigger, the plaque stopped growing and inflammation decreased. This finding could lead to new treatments that target this specific genetic mechanism to help prevent heart attacks and strokes.
Key Statistics
A 2026 research article examining 86 mice and laboratory samples found that blocking circBRWD1 reduced aortic plaque lesion size and decreased necrotic core area in mice with atherosclerosis.
The 2026 study demonstrated that circBRWD1 preferentially increased pro-inflammatory responses in macrophage immune cells, including elevated levels of iNOS, CD86, and pro-inflammatory cytokines.
Research published in 2026 showed that circBRWD1 interacts with miR-141-5p to regulate HMGB1 and downstream NF-kappa-B inflammatory signaling, identifying a specific molecular chain reaction that drives plaque-associated inflammation.
The Quick Take
- What they studied: How a circular piece of genetic material called circBRWD1 causes inflammation that makes heart disease worse
- Who participated: Laboratory mice bred to develop heart disease, plus immune cells grown in dishes to study inflammation
- Key finding: Blocking circBRWD1 reduced plaque buildup in arteries by controlling inflammation in immune cells
- What it means for you: This research identifies a new target for future heart disease treatments, though human studies are still needed before any new drugs reach patients
The Research Details
Researchers used two main approaches to understand how circBRWD1 affects heart disease. First, they studied mice that were genetically programmed to develop atherosclerosis, a condition where plaque builds up in arteries. These mice were fed a high-fat diet to speed up plaque formation. The scientists used genetic tools to turn off circBRWD1 in some mice and compared their results to mice where this genetic material remained active.
Second, they studied immune cells called macrophages in laboratory dishes. These cells are key players in inflammation and plaque buildup. By examining how circBRWD1 worked inside these cells, the researchers could understand the exact steps involved in the inflammatory process. They used multiple techniques including genetic testing, protein analysis, and cell imaging to trace how circBRWD1 communicates with other genetic materials to trigger inflammation.
This combination of animal studies and cell studies allowed researchers to see both the big picture (how plaque develops in whole arteries) and the detailed picture (exactly how genes and proteins interact inside individual cells).
This research approach is important because it bridges the gap between basic science and real disease. By studying both living animals and isolated cells, the researchers could confirm that their findings apply to actual heart disease, not just laboratory conditions. The use of genetic tools to turn off circBRWD1 specifically shows that this genetic material actually causes the problem, rather than just being present when problems occur. This type of evidence is crucial for identifying targets for new medicines.
This study demonstrates several markers of solid research. The scientists used multiple complementary techniques to verify their findings, meaning they didn’t rely on just one method. They studied the problem at different levels, from whole animals down to individual cells and molecules. The use of genetically modified mice that naturally develop heart disease makes the findings more relevant to human disease than studies using artificial conditions. However, because this is animal and cell research rather than human studies, the results need confirmation in people before new treatments can be developed.
What the Results Show
The research revealed that circBRWD1 levels increased as plaque built up in arteries, suggesting this genetic material plays an active role in disease progression. When scientists used genetic tools to reduce circBRWD1 levels in mice, the results were striking: plaque size decreased, fat accumulation in plaques reduced, and the dead tissue cores within plaques shrank. The treated mice also showed fewer signs of cell death in their plaques and lower levels of inflammatory markers throughout their arteries.
Inside immune cells, circBRWD1 acted like a switch that turned up inflammation. When circBRWD1 was present, cells produced more inflammatory proteins and activated more inflammatory pathways. The mechanism worked through a chain reaction: circBRWD1 interacted with a smaller genetic molecule called miR-141-5p, which then controlled a protein called HMGB1. This HMGB1 protein activated a major inflammatory pathway called NF-kappa-B, which is like the master switch for inflammation in cells.
The findings suggest that circBRWD1 acts as a key regulator that keeps inflammation turned on during atherosclerosis. By blocking this genetic material, researchers could essentially turn down the inflammatory volume, allowing plaques to stabilize and shrink.
Beyond the main findings, the study showed that circBRWD1 was especially concentrated in areas of plaques that contained many immune cells, suggesting it specifically affects these inflammation-driving cells. The research also demonstrated that circBRWD1 preferentially increased certain types of inflammatory responses while leaving other immune functions relatively unchanged. This specificity is important because it suggests that targeting circBRWD1 might reduce harmful inflammation without completely shutting down the immune system’s ability to fight infections.
According to Gram Research analysis, this study builds on growing evidence that circular RNA molecules play important roles in heart disease. Previous research had identified these circular genetic materials as regulators of inflammation in various diseases, but their specific role in atherosclerosis was unclear. This work is among the first to map out exactly how a circular RNA controls the inflammatory chain reaction that drives plaque buildup. The findings align with other recent discoveries showing that the miR-141-5p and HMGB1 pathway is important in inflammation, but this is the first study to connect circBRWD1 to this pathway in heart disease.
This research has important limitations to consider. The studies were conducted in mice and laboratory cells, not in humans, so the results may not translate directly to human patients. The mice used were genetically modified to develop heart disease, which is different from how heart disease develops naturally in people. The study focused on one specific genetic mechanism, but heart disease involves many different processes, so blocking just this one target might not be enough to prevent or reverse disease in patients. Additionally, the research examined short-term effects in mice, but heart disease develops over many years in humans, so long-term effects remain unknown. Finally, this work identifies a potential target but does not include any testing of actual drugs or treatments in living animals.
The Bottom Line
Based on this research, there are no direct recommendations for patients yet, as this is early-stage laboratory research. However, the findings suggest that future drug development should focus on blocking circBRWD1 or its interaction with miR-141-5p as a way to reduce plaque-related inflammation. For people concerned about heart disease, current evidence-based recommendations remain important: maintain a healthy diet low in saturated fats, exercise regularly, manage stress, avoid smoking, and work with healthcare providers to control blood pressure and cholesterol. These proven approaches address multiple aspects of heart disease, not just inflammation.
This research is most relevant to people at high risk for heart disease, including those with family histories of early heart attacks or strokes, people with high cholesterol or blood pressure, and those with diabetes. Cardiologists and researchers studying inflammation in heart disease should pay close attention to these findings. However, people should not change their current heart disease prevention or treatment strategies based on this research alone, as human studies are needed first. This work is primarily important for guiding future drug development rather than changing current medical practice.
If circBRWD1 becomes a drug target, the timeline to human treatments would likely be several years at minimum. Typically, promising laboratory findings like these require additional animal studies, safety testing, and then human clinical trials before any new medication becomes available. Patients should continue following current medical advice for heart disease prevention and treatment while researchers work to translate these findings into practical therapies.
Frequently Asked Questions
What is circBRWD1 and why does it matter for heart disease?
CircBRWD1 is a circular piece of genetic material that acts like a switch to turn up inflammation in immune cells. When this switch stays on, it speeds up plaque buildup in arteries. A 2026 study found that blocking this genetic switch reduced plaque formation in mice with heart disease.
How does circBRWD1 cause inflammation in the heart?
CircBRWD1 works through a chain reaction: it interacts with a smaller genetic molecule called miR-141-5p, which controls a protein called HMGB1, which then activates the NF-kappa-B inflammatory pathway. This cascade keeps inflammation turned on in immune cells that contribute to plaque buildup.
Can I get a treatment targeting circBRWD1 right now?
No, this is early-stage research conducted in mice and laboratory cells. Researchers have identified circBRWD1 as a potential drug target, but human studies and drug development are still years away. Continue following current heart disease prevention strategies with your doctor.
Does this research change what I should do to prevent heart disease?
This research doesn’t change current recommendations yet, as it’s laboratory-based. Continue proven approaches: maintain a healthy diet, exercise regularly, manage stress, avoid smoking, and control blood pressure and cholesterol. Future treatments based on this research may provide additional options.
Why did scientists use mice instead of studying humans directly?
Mice with genetically modified heart disease allow researchers to test how blocking circBRWD1 affects disease progression safely and ethically. This early-stage research guides which targets are worth pursuing in human studies. Animal research is a necessary step before human trials can begin.
Want to Apply This Research?
- Users could track inflammatory markers relevant to heart health by recording weekly measurements of blood pressure and resting heart rate, which serve as accessible proxies for cardiovascular inflammation status. Over time, these measurements can reveal trends in cardiovascular health.
- The app could help users implement anti-inflammatory lifestyle changes by suggesting daily activities that reduce inflammation, such as 30 minutes of moderate exercise, eating omega-3 rich foods, managing stress through guided meditation, and tracking sleep quality. Users could log these activities and see how they correlate with their cardiovascular health markers.
- Establish a monthly review where users compare their blood pressure, heart rate, and lifestyle adherence scores to identify patterns. Users could set goals to gradually improve these metrics and receive notifications when they’re trending in the right direction, reinforcing positive behavioral changes that support heart health.
This research represents early-stage laboratory findings in mice and cell cultures. These results have not been tested in humans, and no treatments based on this research are currently available. This article is for educational purposes only and should not be interpreted as medical advice. Anyone concerned about heart disease risk should consult with a healthcare provider about appropriate screening and prevention strategies. Do not change any current medications or treatments based on this research. Future human studies are needed to determine whether blocking circBRWD1 would be safe and effective in people.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.